341 related articles for article (PubMed ID: 8004880)
1. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.
Shirahata A; Kamiya T; Takamatsu J; Kojima T; Fukutake K; Arai M; Hanabusa H; Tagami H; Yoshioka A; Shima GM; Naka GH; Fujita GS; Minamoto Y; Kamizono J; Saito H
Int J Hematol; 2001 Jun; 73(4):517-25. PubMed ID: 11503968
[TBL] [Abstract][Full Text] [Related]
3. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
5. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
6. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
7. Overview of the human pharmacokinetics of recombinant activated factor VII.
Klitgaard T; Nielsen TG
Br J Clin Pharmacol; 2008 Jan; 65(1):3-11. PubMed ID: 17961193
[TBL] [Abstract][Full Text] [Related]
8. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
[TBL] [Abstract][Full Text] [Related]
9. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.
Macik BG; Lindley CM; Lusher J; Sawyer WT; Bloom AL; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Blood Coagul Fibrinolysis; 1993 Aug; 4(4):521-7. PubMed ID: 8218848
[TBL] [Abstract][Full Text] [Related]
10. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
[TBL] [Abstract][Full Text] [Related]
11. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
Brophy DF; Martin EJ; Christian Barrett J; Nolte ME; Kuhn JG; Gerk PM; Carr ME; Pelzer H; Agersø H; Ezban M; Hedner U
Haemophilia; 2011 Sep; 17(5):e949-57. PubMed ID: 21362113
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
Tiede A; Friedrich U; Stenmo C; Allen G; Giangrande P; Goudemand J; Hay C; Holmström M; Klamroth R; Lethagen S; McKenzie S; Miesbach W; Negrier C; Yuste VJ; Berntorp E
J Thromb Haemost; 2011 Jun; 9(6):1191-9. PubMed ID: 21489128
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
Fernández-Bello I; Stenmo C; Butta N; Lind V; Ezban M; Jiménez-Yuste V
Haemophilia; 2017 Nov; 23(6):868-876. PubMed ID: 28851065
[TBL] [Abstract][Full Text] [Related]
14. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
Abshire TC
Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
[TBL] [Abstract][Full Text] [Related]
15. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
Bysted BV; Scharling B; Møller T; Hansen BL
Haemophilia; 2007 Sep; 13(5):527-32. PubMed ID: 17880439
[TBL] [Abstract][Full Text] [Related]
17. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
[TBL] [Abstract][Full Text] [Related]
18. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.
Mahlangu JN; Coetzee MJ; Laffan M; Windyga J; Yee TT; Schroeder J; Haaning J; Siegel JE; Lemm G
J Thromb Haemost; 2012 May; 10(5):773-80. PubMed ID: 22353395
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of recombinant activated factor VII (rFVIIa).
Erhardtsen E
Semin Thromb Hemost; 2000; 26(4):385-91. PubMed ID: 11092213
[TBL] [Abstract][Full Text] [Related]
20. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Qi X; Zhao Y; Li K; Fan L; Hua B
Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
